This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC.
Clinical trial NCT03968419 · TERMINATED
Trial details
- NCT number
- NCT03968419
- Sponsor
- Novartis Pharmaceuticals
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-11-05
- Primary completion
- 2022-04-20
- Enrollment
- 88
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.